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Worldwide, respiratory syncytial virus (RSV) causes severe disease in infants, the elderly, and immu-
nocompromised people. No vaccine or effective antiviral treatment is available. RSV is a member of the
non-segmented, negative-strand (NNS) group of RNA viruses and relies on its RNA-dependent RNA
polymerase to transcribe and replicate its genome. Because of its essential nature and unique properties,
the RSV polymerase has proven to be a good target for antiviral drugs, with one compound, ALS-8176,
having already achieved clinical proof-of-concept efﬁcacy in a human challenge study. In this article,
we ﬁrst provide an overview of the role of the RSV polymerase in viral mRNA transcription and genome
replication. We then review past and current approaches to inhibiting the RSV polymerase, including use
of nucleoside analogs and non-nucleoside inhibitors. Finally, we consider polymerase inhibitors that hold
promise for treating infections with other NNS RNA viruses, including measles and Ebola.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Fig. 1. RSV replication cycle. Schematic illustrating the RSV replication cycle. The
attachment glycoprotein (G protein, red circle) binds to the chemokine receptor,
CX3CR1, on the apical surface of ciliated epithelial cells (Johnson et al., 2015), and the
fusion (F) protein (purple cylinder) mediates entry of the nucleocapsid into the cyto-
plasm (Melero and Mas, 2015). The N-RNA complex (chain of blue circles) serves as a
template for the RSV polymerase complex, consisting of the L and P proteins (orange
and purple ovals, respectively), to synthesize mRNAs and progeny genomes. Tran-
scription also requires the M2-1 protein (yellow circle). The surface glycoproteins are
synthesized, post-translationally modiﬁed, and transported through the endoplasmic
reticulum and exocytic pathway (Collins and Mottet, 1991; Collins and Mottet, 1992;
Olmsted and Collins, 1989). The matrix (M) protein (brown rod) associates with
replication complexes in the cytoplasm and interacts with the cytoplasmic tail of the F
protein to elicit formation of viral ﬁlaments (Baviskar et al., 2013; Ghildyal et al., 2002).
This allows nucleocapsids to be packaged into ﬁlamentous virus particles, which are
released by budding from the cell plasma membrane (Mitra et al., 2012). In addition to
the proteins described above and shown in the ﬁgure, RSV expresses two non-
structural proteins, NS1 and NS2, which act to hinder the innate immune response
to infection (Teng, 2012). RSV also expresses M2-2, which is a negative regulator of
transcription and, by analogy with the closely related human metapneumovirus, might
serve to increase polymerase ﬁdelity (Bermingham and Collins, 1999; Schickli et al.,
2008). The SH protein is a viroporin that alters membrane permeability (Carter
et al., 2010; Gan et al., 2008; Gan et al., 2012). The steps of the RSV life cycle that
are targeted by fusion and replication/transcription inhibitors are highlighted.
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1.1. The burden of RSV infection: an unmet medical need
Respiratory syncytial virus (RSV) causes seasonal infections that
usually last 1e2 weeks and result in mild cold-like symptoms in the
majority of otherwise healthy adults. The RSV season occurs during
winter months in regions with temperate climates in the Northern
and Southern Hemispheres (Yusuf et al., 2007). However, RSV
infection can lead to severe lower respiratory infection in vulner-
able populations such as infants, elderly and immunocompromised
persons. In 2005, an estimated 33.8 million episodes of RSV
occurredworldwide in infants younger than 5 years old. Of these, at
least 3.4million severe cases of lower respiratory infection required
hospitalization, and an estimated 66,000 to 199,000 deaths
occurred, mostly in the developing world (Nair et al., 2010). Severe
RSV infections have also been documented among elderly patients.
RSV infection in the elderly results in approximately 177,000 hos-
pital admissions and approximately 10,000e14,000 deaths per
annum in the United States. Costs associated with hospitalization
are estimated to exceed $1 billion annually (Falsey et al., 2005;
Falsey and Walsh, 2005; Thompson et al., 2003). No vaccines are
approved for the prevention of RSV infection. Palivizumab, a
monoclonal antibody directed against RSV, is approved only for
prophylaxis to prevent serious lower respiratory tract disease
caused by RSV in high-risk infants, but therapeutic efﬁcacy has not
been established (Homaira et al., 2014). Treatment of infants
suffering severe RSV bronchiolitis is thus supportive, consisting of
oxygen therapy, nutrition, and ﬂuids. Ribavirin was approved in
1986 for aerosol treatment of serious RSV infections in hospitalized
children. However, its use is marginal due to the cumbersome route
of administration, concern for potential toxicity for exposed med-
ical personnel, and lack of clear efﬁcacy data (Broughton and
Greenough, 2004). Therefore, novel therapeutics are needed for
use both in the outpatient setting, to reduce the severity of infec-
tion and prevent hospital admissions, and in the hospital setting, to
ameliorate the severity of symptoms and duration of time spent in
the hospital. Since only a few agents for the treatment of RSV
infection are in early stage of clinical development, it is important
to continue to identify and characterize possible targets for inter-
vention with antiviral drugs.
1.2. The RSV replication cycle
RSV is a member of the family Pneumoviridae (previously a
subfamily within the Paramyxoviridae (Afonso et al., 2016)) in the
order Mononegavirales, the non-segmented negative-strand (NNS)
RNA viruses. As such, RSV is a relatively simple virus, with a single-
stranded RNA genome of just over 15 kilobases. RSV consists of two
antigenic subtypes, A and B, subtype A being often associated with
the more severe symptom manifestations. The infection cycle be-
gins when RSV interacts with a receptor at the cell surface and fuses
its envelope with the plasma membrane (Collins et al., 2013)
(Fig. 1). This process delivers the viral nucleocapsid into the cyto-
plasm of the cell. The nucleocapsid consists of the viral genome
RNA, encapsidated along its length with the nucleoprotein (N) to
form a helical structure (Bakker et al., 2013; Maclellan et al., 2007;
Tawar et al., 2009), and associated with the viral RNA-dependent
polymerase, a complex comprising the viral large polymerase
subunit (L), phosphoprotein (P), and a transcription factor, M2-1
(Garcia et al., 1993). Once the nucleocapsid has entered the cyto-
plasm, the polymerase transcribes the viral mRNAs and replicates
the genome by generating a positive-sense RNA intermediate, the
antigenome, which acts as a template for further genome RNA
synthesis (Collins et al., 1984; Collins and Wertz, 1983). Newlysynthesized genomes (and antigenomes) become encapsidated
with N protein as they are synthesized and associate with the po-
lymerase proteins to form nucleocapsids. Nucleocapsids are
transported to the plasma membrane where they associate with
other viral structural proteins, and virions are released by budding.
1.3. Current targets for new anti-RSV treatment candidates
Although every single step of the RSV replication cycle may
represent a potential target for therapeutics, the twomost common
points of intervention are membrane fusion and RNA synthesis
(Fig. 1, for review: (Roymans and Koul, 2010)). Small molecules that
block RSV entry by inhibiting virus-cell fusion and cell-cell syncy-
tium formation have been identiﬁed using in vitro RSV replication
assays (Andries et al., 2003; Bonfanti et al., 2008; Cianci et al., 2004;
Douglas et al., 2003). These compounds bind to a three-fold-
symmetric pocket within the central cavity of the pre-fusion
conformation of RSV F, blocking an important conformational
change needed for membrane fusion (Battles et al., 2016; Samuel
et al., 2015). Although many fusion inhibitors have impressive
antiviral potency in the low-to sub-nanomolar range, most of them
could not be advanced into clinical development due to suboptimal
R. Fearns, J. Deval / Antiviral Research 134 (2016) 63e76 65pharmacokinetic properties or safety liabilities (Roymans and Koul,
2010). To date only one, GS-5806, has shown promise in recent
early-phase clinical trials (DeVincenzo et al., 2014; Mackman et al.,
2015) (for more detailed review on GS-5806: (De Clercq, 2015)).
The efﬁcacy and safety of GS-5806 is currently evaluated in hos-
pitalized adults, including lung transplant and hematopoietic cell
recipients (ClinicalTrials.gov Identiﬁers: NCT02135614,
NCT02534350, NCT02254408, and NCT02254421).
Multiple approaches to block viral RNA synthesis during RSV
replication have been described, including gene silencing by siRNAs
(DeVincenzo, 2012) and targeting the nucleoprotein responsible for
encapsidating the RNA (Challa et al., 2015; Chapman et al., 2007).
One of the most amenable molecular targets for blocking RNA
synthesis is the viral RNA polymerase. As described in detail below,
the RSV polymerase is responsible for transcribing and replicating
the viral genome, by catalyzing at least three enzymatic reactions:
(1) RNA polymerization, for synthesis of the RNAs, (2) a poly-
ribonucleotidyltransferase (or capping) activity, to add a guanosine
cap at the 50 end of mRNAs, and (3) a methyltransferase activity to
methylate the cap. These activities are tightly coordinated to allow
appropriate synthesis of mRNAs and full-length replicative RNAs.
This coordination is essential not only to produce functional RNA
species, but also to avoid generation of abortive RNAs, either
uncapped or double-stranded, that could act as stimulators of the
host innate immune response. Thus, the polymerase is an attractive
prospect for antiviral drug development because of its essential
nature, its multiple activities and target sites, and because a failure
of the polymerase function may stimulate the innate immune
response, potentially augmenting the antiviral effect.
2. Functions and structure of the RSV polymerase complex
2.1. Transcription of mRNAs
Each of the RSV genes is transcribed into a capped and poly-
adenylated mRNA. Transcription of RSV mRNAs involves a complex
interplay between the polymerase and conserved sequence ele-
ments at the boundaries of each of the genes. Fig. 2 shows the
arrangement of cis-acting elements on the RSV genome, and the
products that are generated during transcription. At the beginning
of each gene is a 9- or 10-nucleotide gene start (gs) signal, and at the
end is a 12- or 13-nucleotide gene end (ge) signal (Collins et al.,
1986; Kuo et al., 1997). Between each gene is a short non-
transcribed intergenic region, of varying length and sequence
(Collins et al., 1986). At the 30 and 50 ends of the genome are
extragenic regions, called the leader (le) and trailer (tr), respectively,
which are important for initiation of RNA synthesis (Collins et al.,
1991; Fearns et al., 2002; Mink et al., 1991; Peeples and Collins,
2000). The genome remains encapsidated throughout the replica-
tion cycle, and so the template for the polymerase is a ribonu-
cleoprotein complex, consisting of the RNAwrapped around a chain
of interlocking N molecules (Bakker et al., 2013; Tawar et al., 2009).
Because of the intimate association of RNA with N protein, the N
chain must be transiently displaced to allow the RNA to enter the
polymerization active site of the polymerase. Probably for this
reason, the polymerase can only initiate RNA synthesis from the 30
end of the genome, and not at the beginning of individual genes.
The le region is 44 nucleotides in length and contains a sequence
almost identical to a gs signal at positions 3e12 relative to its 30 end,
which is essential for all RNA synthesis (Fearns et al., 2002;
Tremaglio et al., 2013). To transcribe the genome, the polymerase
begins at position 3, opposite to the gs-like template sequence, and
ﬁrst transcribes a short uncapped RNA transcript, which is variable
in length, but approximately 25 nucleotides (Tremaglio et al., 2013)
(Fig. 2). Having released this RNA, the polymerase remains attachedto the template and can scan to the gs signal for the ﬁrst gene, NS1,
where it reinitiates RNA synthesis (Kuo et al., 1996). Shortly after
reinitiating RNA synthesis, the polymerase adds a guanosine cap
and then elongates the RNA until it reaches a ge signal (Kuo et al.,
1996; Barik, 1993; Liuzzi et al., 2005). The ge signal causes the
polymerase to reiteratively stutter on the U-tract that it contains
and this enables the polymerase to polyadenylate the 30 end of the
mRNA (Harmon et al., 2001). The polymerase then releases the
mRNA and scans the genome until it recognizes another gs signal,
where it reinitiates RNA synthesis (Kuo et al., 1997; Fearns and
Collins, 1999a). By continuing to respond to the gs and ge signals
as it moves from the 30 to the 50 end of the genome, the polymerase
generates a series of capped and polyadenylated mRNAs, corre-
sponding to each of the viral genes. Because the polymerase always
begins transcription at the 30 end of the genome, and because it has
a tendency to dissociate from the genome at the gene junctions, the
genes at the 30 end of the genome are expressed at a somewhat
higher level than those at the 50 end, leading to differential gene
expression (Aljabr et al., 2016; Barik, 1992; Dickens et al., 1984).
2.2. Capping of mRNAs
Most of the research on NNS RNA virus capping has been per-
formed with vesicular stomatitis virus (VSV), a member of the
family Rhabdoviridae, but the mechanisms involved are thought to
be conserved with RSV and other NNS RNA viruses. Messenger
RNAs of NNS RNA viruses require a methylguanosine cap to be
recognized by the cellular translation machinery (Lodish and Rose,
1977; Muthukrishnan et al., 1975) and to remain concealed from
cellular pattern recognition receptors that signal innate immune
responses (Hyde and Diamond, 2015). Furthermore, cap addition
occurs co-transcriptionally and is necessary for the polymerase to
elongate the RNA and respond appropriately to downstream ge and
gs signals (Li et al., 2008; Neubauer et al., 2016; Ogino, 2014;
Galloway and Wertz, 2008; Li et al., 2009; Rose et al., 1977). VSV
capping occurs in two stages: (1) addition of guanosine to the 50
end of the RNA by a 50-50 triphosphate linkage to form GpppRNA
and (2) addition of two methyl groups, one at the ribose 20O posi-
tion of the ﬁrst nucleoside of mRNA and one on the N7 group of the
guanosine cap (Li et al., 2006) (Fig. 3A). Cap addition and methyl-
ation are dependent on interaction between the polymerase and
the conserved sequence at the 50 end of each mRNA (the comple-
ment of the gs signal) (Ogino et al., 2005; Rahmeh et al., 2009;
Stillman and Whitt, 1999; Wang et al., 2007) and the biochem-
istry underlying these reactions is distinct from those of cellular
enzymes. Cellular mRNAs are capped by a guanylyltransferase ac-
tivity, in which the capping enzyme binds covalently to the gua-
nosinemonophosphate moiety of GTP and transfers GMP to an RNA
containing a 50-diphosphate end. In contrast, VSV mRNAs are cap-
ped by an RNA:GDP polyribonucleotidyltransferase (PRNTase) ac-
tivity in which the polymerase binds covalently to a 50-
monophosphorylated RNA and transfers it to the GDP moiety of
GTP (Ogino and Banerjee, 2007, 2010) (Fig. 3B). This is also likely the
case for RSV for which it was also shown that GDP is transferred on
the 50 end of the mRNA (Barik, 1993). Whereas cellular mRNAs are
methylated at the guanine-N-7 position before methylation at the
20-O ribose by two distinct methylases, it has been shown that VSV
polymerase contains a single binding site for the methyl donor, S-
adenosylmethionine, and guanine-N-7 methylation occurs subse-
quent to, and is facilitated by, 20-O methylation (Li et al., 2006;
Rahmeh et al., 2009). Similarly, in studies with human meta-
pneumovirus (a close relative of RSV) 20-O methylation occurred
prior to guanine-N-7 methylation, and in this case, can even occur
prior to addition of the guanosine cap in an in vitro reaction (Paesen
et al., 2015). Thus, while the caps at the 50 ends of the viral mRNAs
Fig. 2. Genome structure of RSV. A, Schematic of the RSV genome and its RNA products. The ten viral genes are shown as purple boxes and each is ﬂanked with a conserved gene
start signal (white box) and gene end signal (black box). At the 30 end of the genome is the leader promoter region (le, green arrow). Transcription results in synthesis of eleven
capped and polyadenylated mRNAs, corresponding to each gene, with the exception of the M2.1 and M2.2 proteins that are both transcribed from the same M2 gene. RNA
replication results in production of an encapsidated antigenome. The trailer (tr) promoter at the 30 end of the antigenome directs initiation of genome RNA synthesis. Both the
genome and antigenome RNAs are encapsidated as they are synthesized and remain associated with N protein (blue circles) throughout the replication cycle. The gene start and gene
end sequences are shown. B, Sequences of the leader and trailer promoter regions. The ﬁrst 55 nucleotides of the genome and antigenome RNAs, containing the leader and trailer
promoter regions, are shown (note that the entire trailer promoter region is 155 nucleotides). The core promoter element in the leader region, required for both transcription and
replication, and the gene start signal for the NS1 gene are shown in red type. The initiation sites in these sequences are indicated with gray arrows.
R. Fearns, J. Deval / Antiviral Research 134 (2016) 63e7666are biochemically indistinguishable from cellular caps, the capping
machinery of the virus is distinct from that of the host, making it a
potentially attractive target for antiviral drugs.
2.3. Genome replication
Genome replication differs frommRNA transcription in a number
of ways. First, during replication the polymerase initiates opposite
the ﬁrst nucleotide of the le promoter rather than opposite the third
nucleotide; second, the polymerase disregards the gs and ge signals
as it moves along the genome; and third, the replicative RNA be-
comes encased with N protein as it is synthesized. These factors are
probably interlinked resulting in replication products that are
uncapped, unpolyadenylated, and encapsidated (Fig. 2). In a similar
manner to transcription, replication initiation also depends on the
gs-like sequence within the le region, but the polymerase initiates
opposite the ﬁrst nucleotide of the template, possibly by becoming
pre-loaded with the initiating nucleoside triphosphates (NTPs)
(Fearns et al., 2002; Noton et al., 2010; Noton and Fearns, 2011).
Whereas during transcription, the polymerase is highly unpro-
cessive in the le region, and can only elongate RNAs efﬁciently
following cap addition, during RNA replication, the polymerase is
super-processive and elongates to the end of the template to
generate the antigenome (Fearns et al., 2002; Noton and Fearns,
2011; Cowton and Fearns, 2005; McGivern et al., 2005). The anti-
genome contains a promoter at its 30 end that is very similar to that
of the le promoter, and signals genome synthesis initiation by asimilar mechanism (Mink et al., 1991; Peeples and Collins, 2000;
Noton et al., 2010). The antigenome and genome RNAs are encap-
sidated as they are synthesized, and the association of the nascent
RNAwith N protein is likely what causes the replicating polymerase
to be processive (McGivern et al., 2005). Encapsidation depends on a
supply of soluble N protein and so RNA replication does not occur
until later in infectionwhenN protein has reached a sufﬁciently high
level. N protein is maintained in a soluble RNA-free form by asso-
ciation with P protein to ensure RNA binding speciﬁcity (Fearns
et al., 1997; Murphy et al., 2003). Encapsidation depends on se-
quences throughout the ﬁrst 35 nucleotides of the le region
including 50pppApC at the 50 end of the RNA (Noton and Fearns,
2011; McGivern et al., 2005). Replicative RNA initiated at position
1 of the le and tr promoters contains 50pppApC, but RNA initiated at
position 3 during transcription initiation does not; one plausible
mechanism for encapsidation initiation is that the RNA sequence at
the 50 ends of the antigenome and genome, including 50pppApC, and
other sequences encoded by the promoters, speciﬁcally interact
with the N-P complex. This initial interaction could function as a
nucleation event, with additional N protein being added by N-N
oligomerization and nucleoprotein-RNA interactions. Alternatively,
the polymerase may play a role in recruiting and delivering N pro-
tein to the nascent RNA (Qanungo et al., 2004).
2.4. Polymerase structure and assignment of functional domains
The core RSV polymerase consists of L and P proteins of 250 and
3)    L-pRNA + Gpp GpppRNA
N7-methylaƟon
2’O-methylaƟon
2)    L + 5’-pppRNA L-pRNA + PPi
4)    GpppRNA + SAM GpppRNA2’m + SAH
5)    GpppRNA2’m + SAM m7GpppRNA2’m + SAH
PRNTase
MTase
5’
5’
3’
Guanosine diphosphate (Gpp)
GTPase 1)    Gppp Gpp + Pi
RNA
Triphosphate
linker
A
B
Fig. 3. Capping of mRNA by NNS RNA viruses. A, Structure of the cap at the 50-end of the viral mRNA. B, Proposed stepwise mechanism of RNA capping by RSV polymerase, based
on vesicular stomatitis virus and other related viruses. Step 1: a molecule of GTP is hydrolyzed to GDP (blue). The transfer of a guanosine at the 50-end of the nascent viral RNA is
provided by the polyribonucleotidyltransferase (PRNTase) activity. Step 2: the L protein forms a covalent intermediate with the 50-end of the nascent RNA after departure of
pyrophosphate (PPi). Step 3: the GDP molecule attacks the phosphodiester bond between L and the RNA, forming the GpppRNA cap product. Step 4: the RNA is methylated (green)
by the methyltransferase (MTase) domain of L, ﬁrst at the 20-position on the ribose of the ﬁrst nucleotide, and then at the N7 of the ﬁrst guanine in the cap structure. S-adenosyl
methionine (SAM, or AdoMet) serves as a co-substrate of the MTase to transfer two methyl groups, leading to the formation of two molecules of S-adenosyl-L-homocysteine (SAH).
For review: (Decroly et al., 2012).
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sufﬁcient for the polymerase to synthesize RNA and respond
appropriately to gs and ge signals (Collins et al., 1995,1996; Grosfeld
et al., 1995; Mazumder and Barik, 1994; Noton et al., 2012; Yu et al.,
1995). However, the L-P complex requires M2-1 as a transcription
elongation factor to be fully processive (Collins et al., 1996),
particularly for mRNAs longer than ~500 nucleotides (Fearns and
Collins, 1999b; Mason et al., 2003). M2-1 is not required for RNA
replication, but in this case elongation is facilitated by concurrent
encapsidation, as described above. Thus, the viral components
required for RSV transcription and replication are the N-RNA
template, the core polymerase L-P, and M2-1 or N-P, respectively.
Currently, high-resolution structures are available for the RSV N-
RNA complex, M2-1, and a fragment of N bound to a peptide of P
(Bakker et al., 2013; Tawar et al., 2009; Ouizougun-Oubari et al.,
2015; Tanner et al., 2014). In addition, a structure for the completeN-P complex of human metapneumovirus has been elucidated
(Renner et al., 2016). As yet, the structure of the L-P complex re-
mains unresolved. This has been difﬁcult due to the large size of the
L protein and the challenges of isolating sufﬁcient quantities of
highly puriﬁed protein. However, the structure of the VSV L protein
in complex with a fragment of P protein has been resolved at high
resolution (Liang et al., 2015) (Fig. 4A). In addition, a crystal struc-
ture of a C-terminal fragment of the human metapneumovirus L
protein has been resolved, showing an overall conserved fold when
compared with the MTase domain of VSV (Paesen et al., 2015)
(Fig. 4B). These breakthroughs in structural studies, combined with
sequence homology and mutational analyses, mean it is now
possible to identify functional domains within the polymerase.
When the amino acid sequences of the L proteins of the NNS
RNA viruses were ﬁrst determined, sequence alignment identiﬁed
six highly conserved regions, I to VI (Poch et al., 1990). In the three-
Fig. 4. Structure of RNA polymerases from viruses related to RSV. A, Structure of
VSV RNA polymerase. The L protein of VSV carries the RdRp function in its N-terminal
region (cyan), followed by the capping functions composed of the PRNTase (green) and
the MTase (orange) activities. B, superimposition between the MTase (orange) and CTD
(red) domains of HMPV and HMPV (gray). VSV protein structure is taken from
PDB ¼ 5a22 (Liang et al., 2015); HMPV protein structure is taken from PDB ¼ 4ucl
(Paesen et al., 2015).
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comprise a “doughnut” structure, with the remainder of the L
protein appearing as four globular appendages (Fig. 4A). Conserved
regions IV and V form a single appendage that is folded over the
hole of the doughnut. Conserved region VI and ﬂanking sequence
are a separate appendage. The two remaining appendages are
referred to as a connector domain and a C-terminal domain, which
comprise a poorly conserved sequence proposed to be involved in
organizing the enzymatically active domains (Liang et al., 2015).
The doughnut has a structure of a right hand, with ﬁngers, palm
and thumb domains, which is characteristic of RNA and DNA
polymerases and contains catalytic motifs shared amongst RdRps
(Noton et al., 2012; Poch et al., 1989; Morin et al., 2012). Conserved
regions IV and V contain the residues required for addition of the
guanosine cap. These include a GxxT motif, which is thought to be
important for NTP binding, and an HR motif, in which the histidine
becomes covalently bound to RNA (Fig. 4A) (Li et al., 2008;
Neubauer et al., 2016; Ogino and Banerjee, 2007, 2010).
Conserved region VI contains a motif similar to that of a ribose 20O
methyltransferase (Bujnicki and Rychlewski, 2002; Galloway et al.,
2008), and the function of this appendage in methylation by VSV L
protein has also been conﬁrmed with biochemical assays (Fig. 4B)
(Rahmeh et al., 2009; Paesen et al., 2015; Li et al., 2005). The sim-
ilarity in structure between RSV and VSV polymerase is unknown.
In any case, both proteins almost certainly undergo signiﬁcant
conformational rearrangement(s) following initiation of RNA syn-
thesis to release the nascent RNA from the active site, and to
facilitate functional interaction between the capping and methyl-
transferase domains and the RNA polymerization domain.3. Inhibitors of RSV polymerase
Recombinant enzymes represent in general a major and well-
deﬁned class of protein targets for drug discovery campaigns.
Although recombinant RSV polymerase can be puriﬁed in func-
tional form (Noton et al., 2012), the use of puriﬁed RSV polymerase
for high-throughput screening has not yet been reported. None-
theless, several RSV inhibitors have been identiﬁed by screening
compounds using infectious RSV, cell-based replicon assays, and an
in vitro assay utilizing nucleocapsids isolated from RSV-infected
cells. Follow-up studies on these compounds have identiﬁed a
number of polymerase inhibitors, including both nucleoside and
non-nucleoside inhibitors. The most extensively characterized
nucleoside and non-nucleoside inhibitors are described below.
3.1. Nucleoside analogs
ALS-8112 e In an effort to discover new chemical scaffolds for
RSV inhibitors, a series of sugar-modiﬁed nucleoside analogs was
screened against the subgroup A serotype of RSV in a cell-culture
virus replication assay (Wang et al., 2015). In parallel, the 50-
triphosphate counterparts were tested against crude isolates of RSV
nucleocapsids containing the active viral RNA polymerase. The
original scaffold identiﬁed from both assayswas 20diﬂuoro-40azido-
cytidine, an analog of gemcitabine also known to inhibit hepatitis C
virus (HCV) polymerase (Smith et al., 2009) (Fig. 5A). Further
modiﬁcations at the 20- and 40- positions aimed to improve anti-
RSV potency and selectivity. This work led to the identiﬁcation of
a series of novel 20- and 40-modiﬁed nucleosides, including ALS-
8112 (Fig. 5A). ALS-8112 did not display any anti-cancer nor anti-
HCV properties, which is different from gemcitabine and
20diﬂuoro-40azido-cytidine. Instead, ALS-8112 inhibited a broad
panel of RSV A and B subtypes, as well as related paramyxo- and
rhabdoviruses (Deval et al., 2015). The polymerization function of
the L protein was identiﬁed as the molecular target of ALS-8112 by
selecting and characterizing drug resistance-associated mutations
located in the L gene. In enzymatic assays, using puriﬁed recom-
binant polymerase, the 50-triphosphate form of ALS-8112 (ALS-
8112-TP) caused immediate chain termination of RNA synthesis
and inhibition of the viral polymerization activity. This inhibitory
effect was speciﬁc, since ALS-8112-TP did not inhibit polymerases
from host or viruses unrelated to RSV such as HCV. To explain the
unfavorable binding of ALS-8112-TP to the active site of HCV po-
lymerase, it was proposed that the side chain of Asn291 may be
responsible for the discrimination of the 40ClCH2 group of the
nucleotide analog (Deval et al., 2015).
ALS-8176 - Because of the low oral bioavailability of ALS-8112, a
series of 20, 30-diester prodrugs were evaluated for improved
pharmacokinetic properties (Wang et al., 2015). One prodrug, ALS-
8176 (Fig. 5B), formed high levels of monophosphate and triphos-
phate forms in the lungs when administered orally to nonhuman
primates. Because of its high oral bioavailability, ALS-8176 was
evaluated for in vivo efﬁcacy in African green monkeys infected
with RSV. At the end of treatment, RSV RNA was undetectable in
bronchoalveolar lavage samples from all four ALS-8176-treated
animals (Deval et al., 2015). This represents a difference in RSV
RNA titers of >4 log10 copies/mL compared to vehicle-treated ani-
mals. Subsequently, a randomized, double-blind, clinical trial
evaluated ALS-8176 given for 5 days to healthy adults inoculated
with RSV (DeVincenzo et al., 2015). The reduction in viral load in
nasal washes associated with ALS-8176 treatment varied from 73%
to 88% depending on the dose regimen. RSV RNAwas undetectable
1.3e2.3 days after the start of ALS-8176 treatment compared with
7.2 days for placebo. Assessment of symptom scores and quantity of
mucus produced also showed a clear effect on RSV-induced disease.
AnƟ-RSV only
Gemcitabine
AnƟ-cancer
AnƟ-RSV /
AnƟ-HCV
AnƟ-RSV /
AnƟ-HCV
Original hit
A
B
RSV A EC50 =  0.15 μM
CC50 > 100 μM
RSVpol IC50 = 0.02 μM
ALS-8112
ALS-8176
RSV A EC50 =  0.26 μM
CC50 >100 μM
In clinical trials
C
RSV A EC50 =  2 μM
CC50 >100 μM
RSVpol IC50 = 0.09 μM
2´F-4´CN C-adenosine
Fig. 5. 2′-ﬂuoro nucleoside analogs inhibiting RSV polymerase. A, Identiﬁcation of 20diﬂuoro-40azido-cytidine as a dual inhibitor of HCV and RSV, leading to the discovery of ALS-
8112 as a speciﬁc inhibitor of RSV (Smith et al., 2009). B, Structure and in vitro antiviral activity of ALS-8176. C, Structure and in vitro antiviral activity of the anti-RSV nucleoside
analog 20F-40CN C-adenosine (Clarke et al., 2015).
Fig. 6. Putative position of ALS-8112-resistance mutations in RSV polymerase. A
homology-based three-dimensional structure of the RdRp domain of the RSV L protein
(blue) was generated using the VSV L protein (cyan, PDB ¼ 5a22). The proposed
positioning of residues 628, 789, 795, and 796 from the RSV polymerase model is
shown in red, and the active site residues GDNQ are indicated with an orange asterisk.
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concept validation that an RSV polymerase inhibitor can be efﬁca-
cious in the clinic.
Resistance to ALS-8112 and ALS-8176 - After 32 in vitro pas-
sages of RSV in the presence of ALS-8112, four mutations were
selected within the region of the L gene of RSV encoding the
polymerization function (Deval et al., 2015). These four amino acid
mutations (M628L, A789V, L795I, and I796V) were associated with
resistance to ALS-8112 and ALS-8176. In biochemical assays, the
presence of the substitutions in recombinant L-P enzyme caused an
increase in discrimination of ALS-8112 triphosphate relative to
natural CTP. The resistance phenotype provided by the mutations
was conferred by the 40ClCH2 moiety of ALS-8112 triphosphate,
with other 40-halomethyl derivatives also being affected (Deval
et al., 2016). This resistance pattern is consistent with the fact
that three of the four amino acid changes are positioned in the
vicinity of conserved region III, which contains the conserved res-
idues 810-GDNQ-813 responsible for nucleotide incorporation by
NNS RNA virus polymerases (Fig. 6) (Malur et al., 2002; Sleat and
Banerjee, 1993). Although the resistance mutations were identi-
ﬁed and characterized from in vitro selection experiments, no
resistant viruses have been identiﬁed in any nasal wash samples
from RSV-infected individuals treated with ALS-8176 as part of the
human challenge study, indicating that ALS-8176 exhibits a high
barrier to viral resistance.Other chemical series with a 20ﬂuoro group e Following up on
the previously identiﬁed 20ﬂuoro nucleosides, a new series of C-
linked nucleosides have been reported (Clarke et al., 2015). One of
Fig. 7. Non-nucleoside inhibitors of RSV polymerase (Part 1). A, Structure and
in vitro antiviral activity of the anti-RSV non-nucleoside inhibitors BI-compound D
(Liuzzi et al., 2005) and (Tiong-Yip et al., 2014). B, Proposed position of amino acids
responsible for the resistance to BI compounds in the capping domain of RSV poly-
merase. Resistance to BI-compound C has been associated with mutation E1269D,
I1381S, and L1421F in RSV L, corresponding respectively to residues E1159, F1265, and
L1311 in VSV L capping domain (side chains shown in red) (Liuzzi et al., 2005). The side
chain of the catalytic histidine from the HR motif in VSV L capping domain is shown in
gray.
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adenosine (20F-40CN C-adenosine, Fig. 5C) inhibited RSV replica-
tion in tissue culture experiments, and its triphosphate form also
inhibited the RNA polymerization activity of RSV polymerase. This
molecule displayed high selectivity against incorporation by
mitochondrial DNA and RNA polymerases, while other analogs
were less selective. The potential for these compounds to be further
developed and tested for in vivo efﬁcacy will depend on their ca-
pacity to form high levels of NTPs in lung tissues upon oral dosing
in animals and humans, which remains unknown. Additionally,
escape mutations associated with resistance to 20F-40CN C-adeno-
sine from in vitro RSV passaging experiments have not yet been
reported.
3.2. Non-nucleoside inhibitors
BI-compound D - A few years ago, the ingenious adaptation of
an enzyme assay designed to capture transcripts in a microplate
format uncovered a series of RSV polymerase complex inhibitors
(Mason et al., 2004). The principle of the assay is simple: a crude
isolate of RSV nucleocapsids is incubated in a transcription buffer
containing radiolabeled NTP. The radiolabeled polyadenylated
mRNA products of the RSV polymerase (Long strain) are captured
by strand complementation using an oligo(dT) probe coupled to
biotin. Using this approach, a weak inhibitor of RSV transcription,
designated BI-compound A, was identiﬁed. Several analogs, such as
BI-compound D (BI-D), were synthesized to optimize the inhibition
potency by about 50-fold compared to BI-compound A (Fig. 7A)
(Liuzzi et al., 2005). Some of the analogs in the imidazoquinolines
family not only prevented replication of infectious particles in cell
culture, but also inhibited the RSV polymerase-dependent tran-
scription of a minigenome. However, the in vivo antiviral effect in a
murine model was very modest. Three amino acid residues, origi-
nally selected in vitro with BI-compound C, confer resistance to this
series of inhibitors. They are located within conserved region V of
the L protein, the domain responsible for cap addition (Fig. 7B)
(Liuzzi et al., 2005). Experiments studying the mechanism of in-
hibition by BI-D showed that it inhibited full-length mRNA syn-
thesis and instead caused the production of aborted ~40e50
nucleotide length transcripts containing a 50 triphosphate moiety
(Liuzzi et al., 2005), consistent with a capping defect. In addition,
BI-D has been shown to affect polymerase processivity within the
promoter region (McCutcheon et al., 2015), indicating it has mul-
tiple effects on polymerase function. Interestingly, RSV-infected
cells treated with BI-D secreted higher levels of interferon and
expressed higher levels of interferon-stimulated genes than infec-
ted untreated cells, despite the fact that untreated cells contained
considerably more RSV RNA (McCutcheon et al., 2015). This sug-
gests that the abortive RSV transcripts produced in the presence of
BI-D potentiated the interferon response, probably through the
RIG-I pathway. Thus, inhibitors that target the capping activity of
the RSV polymerase have the potential to activate the innate im-
mune response in addition to inhibiting the polymerase, which
could increase their potency. However, further evaluation is
necessary to determine if such inhibitors cause increased
immunopathology.
YM-53403 - In cases where it is not possible to implement high-
throughput enzymatic assays, cell-based assays remain a viable
option for screening of large number of compounds. Resistance
selection and target validation by reverse genetics are used later on
for validating the mechanism of action of newly discovered in-
hibitors. A good example of this approach is YM-53403 (Fig. 8A), an
inhibitor of RSV from a benzazepine series discovered bymeasuring
the cytopathic effect associated with virus replication (Sudo et al.,
2005). In this cell-based high-throughput screening campaign,some compounds identiﬁed in the primary screen were up to 100-
fold more potent against RSV than ribavirin. YM-53403 emerged as
one of the most promising molecules from this series. Although it
was originally reported to be active against RSV subtype B (Sudo
et al., 2005), this result could not be conﬁrmed in a subsequent
study (Tiong-Yip et al., 2014). When cells were repeatedly infected
in the presence of YM-53403, the selection of a single mutation
Y1631H within the L gene made the mutated virus completely
insensitive to the inhibitory effect of YM-53403. Although no
detailed mechanistic studies have been reported, in an in vitro
assay using recombinant RSV polymerase, YM-53403 inhibited RNA
synthesis from a promoter template (McCutcheon et al., 2015),
indicating that it has a similar mechanism of inhibition as one of its
derivatives, AZ-27, described below.
AZ-27 - Other derivatives of YM-53403 were synthesized to
increase the inhibitory potency against RSV (Xiong et al., 2013). In
particular, the compound AZ-27 (Fig. 8A) had an EC50 ¼ 0.01 mM
against RSV subtype A and an EC50 ¼ 1.3 mM against RSV subtype B
(Tiong-Yip et al., 2014). The in vitro antiviral potency of AZ-27 was
speciﬁc to RSV, with no inhibition observed against meta-
pneumovirus, inﬂuenza A virus, human rhinovirus, or
BRD9101 
RSV A EC50 =  1.7/4.3 μM 
RSV B EC50 >50 μM 
CC50 >100 μM 
BRD3969 
RSV A EC50 =  1.6/4.2 μM 
RSV B EC50 >50 μM 
CC50 ~50 μM 
Compound-1 
RSV A EC50 =  1.6 μM 
RSV B EC50 >100 μM 
CC50 >100 μM 
B  
YM-53403 AZ-27 
RSV A EC50 =  0.01 μM 
RSV B EC50 = 1.3 μM 
CC50 >100 μM 
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Fig. 8. Non-nucleoside inhibitors of RSV polymerase (Part 2). A, Structure and in vitro antiviral activity of the anti-RSV non-nucleoside inhibitors YM-53403 (Sudo et al., 2005),
and AZ-27 (Tiong-Yip et al., 2014). All EC50 and CC50 values are reported from (Tiong-Yip et al., 2014). B, Structure and in vitro antiviral activity of the anti-RSV non-nucleoside
inhibitors Compound-1 (Laganas et al., 2014), BRD9101 and BRD3969 (Duvall et al., 2016). For BRD9101 and BRD3969, the ﬁrst EC50 value is from a CPE reduction infectious assay,
and the second from a sub-genomic replicon assay.
R. Fearns, J. Deval / Antiviral Research 134 (2016) 63e76 71cytomegalovirus. Experiments performed with the RSV mini-
genome and recombinant polymerase complex showed that AZ-27
inhibited the initiation of de novo RNA synthesis at the promoter,
resulting in inhibition of both mRNA transcription and genome
replication to the same extent (Noton et al., 2015). The Y1631H
mutation that had previously been identiﬁed with YM-53403
conferred cross-resistance to AZ-27 (Tiong-Yip et al., 2014), but
not against nucleotide analogs (Deval et al., 2016). Instead, it was
found that, when combined, the nucleoside analog ALS-8112 and
AZ-27 acted in synergy to inhibit RSV replication. Y1631 lies in a
poorly conserved linker region between the connector domain and
the methyltransferase domain in conserved region VI. It is not
present within the C-terminal crystal structure of HMPV L protein
and this regionwas not traced on the VSV L structure because it is in
a poorly ordered linker. Therefore, the mechanism by which AZ-27
inhibits RNA synthesis initiation remains elusive. While Y1631 is
proximal to the RNA capping and methylation domains of RSV
polymerase, it is conceivable that AZ-27 could interfere with one of
these functions, although the data obtained so far clearly show thatthe dominant inhibition effect is on RNA synthesis initiation (Noton
et al., 2015).
Other molecules that induce the selection of the Y1631H mu-
tation - Interestingly, the same Y1631H substitution was observed
in an independent study where novel candidates were found by
screening a sub-genomic RSV replicon against a library of about one
million compounds (Laganas et al., 2014). One of the most potent
inhibitors identiﬁed in this studywas a thymine derivative, referred
to as Compound-1 (Fig. 8B). Compound-1 is in a distinct structural
class from YM-53403 and AZ-27 and induced the double selection
of Y1631H and I1413T in the L protein. In this case, the Y1631H
substitution was shown to be the most important for conferring
resistance. As with YM-53403 and AZ-27, Compound-1 also
showed greater potency against RSV subgroup A than against
subgroup B viruses. Similar results were also obtained with related
compounds from a separate series, BRD9101 and BRD3969 (Duvall
et al., 2016) (Fig. 8B). Themechanisms of inhibition by Compound 1,
BRD9101 and BRD3969 have not yet been determined, but the
mechanism of inhibition of BRD3969 appears to be distinct from
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same resistance mutation can be selected by multiple compound
scaffolds in independent screening campaigns suggests that tyro-
sine 1631 may be in a “hot spot” for inhibition by small molecules,
but that different molecules have different effects on polymerase
activity. Alternatively, it is possible that this substitution causes
structural alterations in the polymerase that allow it to perform its
activities, but that prevent these small molecules from binding
other sites.
4. Inhibitors of RNA polymerases of viruses related to RSV
The order Mononegavirales includes a number of important
human pathogens including measles, mumps, parainﬂuenza,
rabies, Ebola, and Marburg viruses. These viruses differ in terms of
pathogenesis, tropism, immune evasion, and mechanisms of viral
entry and assembly. However, the overall strategy of mRNA tran-
scription and genome replication, described above for RSV, is likely
to be conserved between all NNS RNA viruses. Furthermore, since
the polymerase regions directly involved in enzymatic activities are
conserved, the structural elements and biochemical mechanisms
underlying RNA polymerization, cap addition, and cap methylation
are likely to be similar. Studies on measles, Marburg, and Ebola
viruses have identiﬁed additional inhibitors, some of which are
broad spectrum and have activity against RSV aswell. The following
section reviews molecules either inhibiting a speciﬁc NNS RNA vi-
rus polymerase other than that of RSV, or that display broad anti-
Mononegavirales polymerase activity.
4.1. Measles polymerase inhibitors
ERDRP-0519 e Measles virus RNA polymerase inhibitors have
been discovered by screening a library of >30,000 molecules
(Ndungu et al., 2012; Sun et al., 2008; White et al., 2007). This
screening campaign used recombinant viruses containing a re-
porter gene, which presented several advantages compared to wild
type virus, such as the ease of use and the strength of the signal.
Again, the absence of biochemical or structural data was compen-
sated by reverse genetics experiments to determine the viral target
and inhibitor binding site of structurally related compounds such as
AS-136a and ERDRP-0519 (Krumm et al., 2014; Yoon et al., 2009)
(Fig. 9A). Prolonged incubation of measles-infected cells in the
presence of these small molecules induced the selection of multiple
resistance mutations, including a T776A mutation in the L gene of
measles. The mutated residue is in close proximity to the GDNQ
motif within conserved region III of the L protein that is responsible
for RNA polymerization activity. The ERDRP-0519 inhibitor is active
in vivo in a ferret model of infection (Krumm et al., 2014). The
precise mechanism of inhibition of these molecules remains to be
determined. For example, it is not known whether they interact
with the polymerase at the time of initiation or elongation of RNA
synthesis. In any case, this result is an important step towards
demonstrating that it is possible to achieve strong in vivo efﬁcacy
using non-nucleoside molecules targeting the RNA polymerase of a
paramyxovirus related to RSV and other pneumoviruses.
4.2. Filovirus polymerase inhibitors
T-705 - The nucleoside precursor 6-ﬂuoro-3-hydroxy-2-
pyrazinecarboxamide (T-705, favipiravir) was originally devel-
oped against inﬂuenza virus (for review: (Furuta et al., 2013)). The
molecule has also been shown to inhibit a number of other RNA
viruses including members of Orthomyxo-, Noro-, Bunya-, Arena-,
and Flaviviridae (Furuta et al., 2013). In vitro, the antiviral potency
of T-705 against Ebola replication is very weak, with an EC50 valueof 67 mM (Fig. 9B) (Oestereich et al., 2014). Nonetheless, treatment
with T-705 given orally resulted in 100% survival in a lethal Ebola-
infected mouse model (Oestereich et al., 2014; Smither et al., 2014).
It has been proposed that T-705 exerts its activity by targeting viral
polymerases, although this has not been demonstrated in the case
of Ebola virus. In cells, T-705 is efﬁciently converted to a ribofur-
anosyl 50-triphosphate form (T-705 RTP) by cellular enzymes
(Furuta et al., 2009). The RNA polymerases of inﬂuenza virus and
norovirus recognize T-705 RTP as substrate during RNA synthesis,
which results in enzyme inhibition by delayed chain termination
(Furuta et al., 2005; Jin et al., 2013, 2015). It has also been suggested
that T-705 causes error catastrophe as a consequence of intro-
ducing lethal mutations (Baranovich et al., 2013). Sissoko et al.
recently reported the experimental use of T-705 in Ebola-infected
patients during the peak of the 2014e2015 outbreak in Guinea
(Sissoko et al., 2016). Although T-705 was well tolerated, it did not
provide any signiﬁcant antiviral effect. In this context, more work
will be needed to understand the precise mechanism of action of T-
705 against Ebola virus and its actual potential as an anti-Ebola
agent, alone or in combination.
BCX4430 - BCX4430 is an adenosine analog with a C-nucleo-
side base modiﬁcation and 10-imino group on the sugar moiety
(Fig. 9B). BCX4430 is also a broad-spectrum agent that shows
weak in vitro antiviral activity not only against positive-strand
RNA viruses such as rhinovirus (EC50 ¼ 3 mM) and dengue virus
(EC50 ¼ 33 mM), but also against negative-strand RNA viruses such
as inﬂuenza (EC50 ¼ 11 mM), RSV (EC50 ¼ 11 mM), Ebola
(EC50 ¼ 11.8 mM) and Marburg viruses (EC50 ¼ 4.4e6.7 mM)
(Warren et al., 2014). In a macaque lethal model of Marburg virus
disease, treatment with BCX4430 resulted in 100% protection,
even when administered 48 h post-infection. Similarly to what
was observed with T-705, it is not known why BCX4430 is efﬁ-
cacious in vivo despite its weak in vitro inhibition potency. Based
on biochemical experiments performed with recombinant HCV
polymerase, it has been proposed that BCX4430 targets viral RNA
polymerases and acts as a non-obligate chain terminator. BCX4430
is currently in Phase I clinical trials to evaluate safety, tolerability
and pharmacokinetics in healthy volunteers (ClinicalTrials.gov
Identiﬁer: NCT02319772).
GS-5734 - Other C-linked nucleoside analogs have been re-
ported recently as anti-Ebola agents (Warren, 2015). Adding a 10-
cyano group to a C-linked adenosine provided potency against
Ebola virus polymerase and selectivity for viral polymerases
(Fig. 9C). In tissue culture experiments, the parent nucleoside GS-
441524 was moderately active against Ebola replication with EC50
values around 1.5 mM. Its weak antiviral activity may be attributed
to inefﬁcient intracellular phosphorylation, whichwas improved by
adding a monophosphate prodrug to the parent nucleoside
(Fig. 9C). The resulting compound, GS-5734, is a broad-spectrum
inhibitor with efﬁcacy against a variety of viruses, including RSV.
It inhibits the Zaire and Sudan species of Ebola virus and Marburg
virus with EC50 values ranging from 0.01 to 0.20 mM, and exhibits
moderate cytotoxicity (CC50¼ 2 to > 20 mM) in multiple human cell
types (Warren et al., 2016). The favorable in vitro data led to further
evaluation of GS-5734 in a macaque lethal model of Ebola virus
disease. Complete protection was achieved when GS-5734 was
administered at a daily intravenous dose of 10 mg/kg, beginning on
Day 3 post-infection. Following Phase I safety testing in healthy
human volunteers, GS-5724 was ﬁrst given for compassionate use
in October 2015 to an Ebola-infected patient when a nurse who had
survived the disease developed a recurrence in the central nervous
system (Jacobs et al., 2016). In conclusion, GS-5734 represents the
ﬁrst Ebola polymerase inhibitor to demonstrate robust therapeutic
efﬁcacy in a non-human primate model and reach evaluation of
safety and efﬁcacy in human clinical trials.
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Fig. 9. Inhibitors of measles and Ebola virus polymerases. A, Structure and in vitro antiviral activity of the measles virus inhibitors AS-136a and ERDRP-00519 (Ndungu et al.,
2012; Sun et al., 2008; White et al., 2007). B, Structure and in vitro antiviral activity of the Ebola virus inhibitors T-705 (Oestereich et al., 2014), and BCX4430 (Warren et al.,
2014). C, Structure and in vitro antiviral activity of the Ebola virus inhibitors GS-441524 and GS-5734 (Warren et al., 2016).
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In this review, we have summarized the efforts taken to develop
inhibitors of NNS RNA virus polymerases, focusing mainly on RSV
for which most molecules have been identiﬁed. We have discussed
inhibitors of RSV RNA polymerase that are either nucleoside ana-
logs targeting the active site of the polymerization domain, or non-
nucleoside inhibitors binding to other regions of the polymerase.
Currently, the most clinically advanced drug candidate for RSV
infection is the nucleoside analog ALS-8176, which acts as a chain
terminator of RNA synthesis. In general, the mechanism of action of
non-nucleoside inhibitors of RSV polymerase is less well under-
stood. Given that the polymerase likely undergoes multiple
conformational changes to initiate RNA synthesis, elongate, cap,
and methylate the RNA, non-nucleoside inhibitors might have
allosteric effects that impact multiple activities. The latest Ebola
virus crisis has served as a reminder that it is extremely challenging
to conduct antiviral drug discovery in response to a rapidly
expending epidemic and has highlighted the need for continued
research on the polymerases of a variety of human pathogens. Therecent Ebola drug discovery efforts also highlighted that its viral
RNA polymerase represents a viable target for small molecule in-
hibitors. The fact that inhibitors such as GS-5734 are active against
Ebola virus and RSV opens up the possibility that in future, in-
hibitors approved for use against a highly prevalent virus, such as
RSV, might have the potential for being deployed against rare
emerging threats, such as Ebola, Marburg and Nipah viruses.
Key future research directions to advance polymerase inhibitors
as antiviral treatments include elucidation of the structures of the
polymerase of RSV and other related human pathogens, including
structures of the polymerase in association with ligands and at
different stages of RNA synthesis. This is necessary to provide a
better mechanistic understanding of modes of inhibition, and
improve molecule design. In addition, the possibility of combining
inhibitors for synergistic effects should be explored; for example,
the combination of ALS-8112 with AZ-27 had a synergistic effect on
inhibition of RSV replication in vitro (Deval et al., 2016). This
combination approach might raise the barrier to resistance and
increase antiviral efﬁcacy. As more polymerase inhibitors progress
into clinical trials, there will be greater opportunity to evaluate
R. Fearns, J. Deval / Antiviral Research 134 (2016) 63e7674synergistic effects between drugs and determine the likelihood of
broad cross-resistance.
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L large polymerase subunit
le leader promoter
M matrix protein
MTase methyltransferase
N nucleoprotein
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NTP nucleoside triphosphate
P phosphoprotein
PPi pyrophosphate
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RdRp RNA-dependent RNA polymerase
RSV respiratory syncytial virus
RT reverse transcriptase
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SAM S-adenosyl methionine
TP triphosphate
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